{
    "nctId": "NCT00880464",
    "briefTitle": "Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer",
    "officialTitle": "A Phase Ib Study of Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete GM-CSF Following Preoperative Chemotherapy in Women With Operable Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Minimum Number of Vaccine Doses Created Using Participant Tumor Sample",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed invasive breast cancer, pre-operative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging\n* Cohort 1: At least 2cm of residual disease in sum of diameters by clinical or radiographic findings following their preoperative chemotherapy\n* Cohort 2: Patients who have not received preoperative chemotherapy must have at least 4cm of disease in the largest diameter by clinical or radiographic findings\n* Prior therapy for Cohort 1 only: Must have completed preoperative (neoadjuvant) chemotherapy with either a standard regimen (containing an anthracycline and/or a taxane) or on a clinical trial\n* HER2 positive tumors must have received at least one prior trastuzumab-based therapy, and may not receive concurrent trastuzumab therapy and vaccination\n* Must initiate hormonal therapy (if indicated), including ovarian suppression, at least 4 weeks prior to initiation of vaccinations\n* Must have completed definitive resection of primary tumor with adequated excision of gross disease. Surgery should have occured more than 28 days but within 12 weeks prior to enrollment\n* May receive concurrent hormonal therapy, such as tamoxifen, ovarian suppression, and aromatase inhibitors\n* Must have had prior banked tumor of sufficient cellular yield for vaccination\n* ECOG Performance Status 0 or 1\n* 18 years of age or older\n* Greater than 4 weeks from immunotherapy, or systemic glucocorticoid therapy\n* Adequate recovery from recent surgery and radiation therapy\n\nExclusion Criteria:\n\n* Uncontrolled active infection or illness\n* Other medical or psychiatric illness or social situation that would limit study compliance\n* Pregnancy or nursing mothers\n* Evidence of HIV infection\n* Previous participation in an adenovirus-based trial\n* Concurrent invasive malignancies",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}